Since we found that ERBIN plays a suppressive role in cancer development, pharmacologically targeting TGF‐β signaling in cancer cells may restore ERBIN expression and inhibit EMT induced by both TGF‐β stimulation and ERBIN downregulation. This evidence concerns the gene TGFB1 and cancer.